Researchers have found that induced pluripotent stem cell–derived cardiomyocytes from a patient with arrhythmogenic cardiomyopathy recapitulate the reduced contractility and impaired desmosome assembly associated with this disease, providing a rapid and convenient platform for developing new treatments such as gene replacement therapy.